The cardiovascular risk marker asymmetric dimethylarginine is elevated in asymptomatic, untreated HIV-1 infection and correlates with markers of immune activation and disease progression
- 18 October 2013
- journal article
- Published by SAGE Publications in Annals of Clinical Biochemistry: International Journal of Laboratory Medicine
- Vol. 51 (5) , 568-575
Abstract
Background: As lifespan in HIV infection increases, cardiovascular disease has emerged as a cause of morbidity and mortality. Asymmetric dimethylarginine is an established marker of endothelial dysfunction and predicts cardiovascular events. The role of asymmetric dimethylarginine in HIV-related cardiovascular disease has not been established. Our aim was to determine whether asymmetric dimethylarginine concentrations were elevated in treatment naïve, HIV-infected subjects and to correlate these with markers of immune activation and disease progression. Methods: Serum samples were collected from HIV-positive and -negative subjects attending a primary health care clinic over a 12-month period. Asymmetric dimethylarginine concentrations were measured and correlated with CD4 count, viral load, hsCRP, IL-6, IgG, adenosine deaminase and CD8/38 T lymphocytes. Results: Sixty HIV-positive participants (mean age 32.0 years) and 20 HIV-negative controls (mean age 32.4 years) were studied. All were of black ethnicity. The mean asymmetric dimethylarginine concentration in the infected group measured 0.67 µmol/L (95% CI 0.62–0.72 µmol/L) which was significantly higher than in the control group of 0.48 µmol/L (95% CI 0.40–0.56 µmol/L). Asymmetric dimethylarginine correlated inversely with CD4 counts and positively with IgG, adenosine deaminase and CD8/38 T lymphocytes. No significant correlation was found with hsCRP, IL-6, or viral load. Conclusion: We demonstrated that asymmetric dimethylarginine is elevated in HIV infection, in patients with relatively well-preserved CD4 counts not yet on anti-retroviral treatment. We showed significant correlations of asymmetric dimethylarginine with CD8/38 T lymphocytes, IgG and adenosine deaminase, suggesting that T-cell activation and the adaptive immune response underlie asymmetric dimethylarginine elevation in this population.Keywords
This publication has 44 references indexed in Scilit:
- Effects of HIV Infection and Antiretroviral Therapy on the Heart and VasculatureCirculation, 2008
- Asymmetric Dimethylarginine Enhances Cardiovascular Risk Prediction in Patients With Chronic Heart FailureArteriosclerosis, Thrombosis, and Vascular Biology, 2007
- Increased Acute Myocardial Infarction Rates and Cardiovascular Risk Factors among Patients with Human Immunodeficiency Virus DiseaseThe Journal of Clinical Endocrinology & Metabolism, 2007
- Asymmetrical Dimethylarginine Independently Predicts Total and Cardiovascular Mortality in Individuals with Angiographic Coronary Artery Disease (The Ludwigshafen Risk and Cardiovascular Health Study)Clinical Chemistry, 2007
- Asymmetrical Dimethylarginine Predicts Progression to Dialysis and Death in Patients with Chronic Kidney DiseaseJournal of the American Society of Nephrology, 2005
- Cardiovascular Risk and Body-Fat Abnormalities in HIV-Infected AdultsNew England Journal of Medicine, 2005
- Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD studyAIDS, 2003
- Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective studyThe Lancet, 2001
- Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: acohort studyThe Lancet, 1999
- Atherosclerosis — An Inflammatory DiseaseNew England Journal of Medicine, 1999